Prophylaxis, Diagnosis and Therapy of Hepatitis B Virus (HBV) Infection: The German Guidelines for the Management of HBV Infection

M. Cornberg; U. Protzer; M. M. Dollinger; J. Petersen; H. Wedemeyer; T. Berg; W. Jilg; A. Erhardt; S. Wirth; P. Schirmacher; W. E. Fleig; M. P. Manns

doi:10.1055/s-2007-963714

Zeitschrift für Gastroenterologie, Inhaltsverzeichnis

Z Gastroenterol 2007; 45(12): 1281-1328
DOI: 10.1055/s-2007-963714

Leitlinie

Prophylaxis, Diagnosis and Therapy of Hepatitis B Virus (HBV) Infection: The German Guidelines for the Management of HBV Infection[1]

Prophylaxe, Diagnostik und Therapie der Hepatitis-B-Virus-(HBV-)InfektionM. Cornberg¹ , U. Protzer² , M. M. Dollinger³ , J. Petersen⁴ , H. Wedemeyer¹ , T. Berg⁵ , W. Jilg⁶ , A. Erhardt⁷ , S. Wirth⁸ , P. Schirmacher⁹ , W. E. Fleig¹⁰ , M. P. Manns¹

¹Abteilung Gastroenterologie, Hepatologie und Endokrinologie, Medizinische Hochschule Hannover
²Institut für Virologie, Technische Universität München/Helmholtz Zentrum München
³Klinik und Poliklinik für Innere Medizin I, Martin-Luther-Universität Halle
⁴I. Medizinische Klinik und Poliklinik, Universitätsklinikum Hamburg-Eppendorf
⁵Medizinische Klinik m. S. Hepatologie und Gastroenterologie, Charité, Campus Virchow-Klinikum, Humboldt-Universität zu Berlin
⁶Institut für Medizinische Mikrobiologie und Hygiene, Universität Regensburg
⁷Klinik für Gastroenterologie, Hepatologie und Infektiologie, Universitätsklinikum Düsseldorf, Heinrich-Heine-Universität Düsseldorf
⁸Zentrum für Kinder- und Jugendmedizin, HELIOS-Klinikum Wuppertal, Universität Witten/Herdecke
⁹Pathologisches Institut, Universitätklinikum Heidelberg
¹⁰Universitätsklinikum, Universität Leipzig

Abstract

Volltext

Referenzen

References

1 Immunisation against hepatitis B. Lancet. 1988; 1 875-876
2 Are booster immunisations needed for lifelong hepatitis B immunity? European Consensus Group on Hepatitis B Immunity. Lancet. 2000; 355 561-565
3 Ahmed A, Keeffe E B. lamivudinee therapy for chemotherapy-induced reactivation of hepatitis B virus infection. Am J Gastroenterol. 1999; 94 249-251
4 Anandh U, Bastani B, Ballal S. Granulocyte-macrophage colony-stimulating factor as an adjuvant to hepatitis B vaccination in maintenance hemodialysis patients. Am J Nephrol. 2000; 20 53-56
5 Anselmo D M, Ghobrial R M, Jung L C. et al . New era of liver transplantation for hepatitis B: a 17-year single-center experience. Ann Surg. 2002; 235 611-619
6 Arribas J R, Gonzalez-Garcia J J, Lorenzo A. et al . Single (B or C), dual (BC or BD) and triple (BCD) viral hepatitis in HIV-infected patients in Madrid, Spain. AIDS. 2005; 19 1361-1365
7 Arslan M, Wiesner R H, Sievers C. et al . Double-dose accelerated hepatitis B vaccine in patients with end-stage liver disease. Liver Transpl. 2001; 7 314-320
8 Ascherio A, Zhang S M, Hernan M A. et al . Hepatitis B vaccination and the risk of multiple sclerosis. N Engl J Med. 2001; 344 327-332
9 Averhoff F, Mahoney F, Coleman P. et al . Immunogenicity of hepatitis B Vaccines. Implications for persons at occupational risk of hepatitis B virus infection. Am J Prev Med. 1998; 15 1-8
10 Awerkiew S, Daumer M, Reiser M. et al . Reactivation of an occult hepatitis B virus escape mutant in an anti-HBs positive, anti-HBc negative lymphoma patient. J Clin Virol. 2007; 38 83-86
11 Ayoola E A, Johnson A O. Hepatitis B vaccine in pregnancy: immunogenicity, safety and transfer of antibodies to infants. Int J Gynaecol Obstet. 1987; 25 297-301
12 Aziz A, Aziz S, Li D S. et al . Efficacy of repeated high-dose hepatitis B vaccine [80 microg) in patients with chronic liver disease. J Viral Hepat. 2006; 13 217-221
13 Bae S H, Yoon S K, Choi J Y. et al . Timing of lamivudine administration according to Child class in patients with decompensated cirrhosis. J Gastroenterol Hepatol. 2005; 20 1527-1532
14 Banatvala J, Van Damme P, Oehen S. Lifelong protection against hepatitis B: the role of vaccine immunogenicity in immune memory. Vaccine. 2000; 19 877-885
15 Bauer T, Jilg W. Hepatitis B surface antigen-specific T and B cell memory in individuals who had lost protective antibodies after hepatitis B vaccination. Vaccine. 2006; 24 572-577
16 Benhamou Y. Treatment algorithm for chronic hepatitis B in HIV-infected patients. J Hepatol. 2006; 44 S90-S94
17 Benhamou Y, Bochet M, Thibault V. et al . Long-term incidence of hepatitis B virus resistance to lamivudine in human immunodeficiency virus-infected patients. Hepatology. 1999; 30 1302-1306
18 Benhamou Y, Thibault V, Vig P. et al . Safety and efficacy of adefovir dipivoxil in patients infected with lamivudine-resistant hepatitis B and HIV-1. J Hepatol. 2006; 44 62-67
19 Benner K G, Lee R G, Keeffe E B. et al . Fibrosing cytolytic liver failure secondary to recurrent hepatitis B after liver transplantation. Gastroenterology. 1992; 103 1307-1312
20 Benvegnu L, Fattovich G, Noventa F. et al . Concurrent hepatitis B and C virus infection and risk of hepatocellular carcinoma in cirrhosis. A prospective study. Cancer. 1994; 74 2442-2448
21 Berger A, Doerr H W, Rabenau H F. et al . High frequency of HCV infection in individuals with isolated antibody to hepatitis B core antigen. Intervirology. 2000; 43 71-76
22 Bienzle U, Gunther M, Neuhaus R. et al . Immunization with an adjuvant hepatitis B vaccine after liver transplantation for hepatitis B-related disease. Hepatology. 2003; 38 811-819
23 Bodsworth N, Donovan B, Nightingale B N. The effect of concurrent human immunodeficiency virus infection on chronic hepatitis B: a study of 150 homosexual men. J Infect Dis. 1989; 160 577-582
24 Bodsworth N J, Cooper D A, Donovan B. The influence of human immunodeficiency virus type 1 infection on the development of the hepatitis B virus carrier state. J Infect Dis. 1991; 163 1138-1140
25 Bortolotti F. Treatment of chronic hepatitis B in children. J Hepatol. 2003; 39 (Suppl 1] S200-S205,
26 Bortolotti F, Guido M, Bartolacci S. et al . Chronic hepatitis B in children after e antigen seroclearance: final report of a 29-year longitudinal study. Hepatology. 2006; 43 556-562
27 Bortolotti F, Jara P, Barbera C. et al . Long term effect of alpha interferon in children with chronic hepatitis B. Gut. 2000; 46 715-718
28 Brook G. Prevention of viral hepatitis in HIV co-infection. J Hepatol. 2006; 44 S104-S107
29 Brook M G, Chan G, Yap I. et al . Randomised controlled trial of lymphoblastoid interferon alpha in Europid men with chronic hepatitis B virus infection. BMJ. 1989; 299 652-656
30 Brook M G, McDonald J A, Karayiannis P. et al . Randomised controlled trial of interferon alpha 2A (rbe) (Roferon-A) for the treatment of chronic hepatitis B virus (HBV) infection: factors that influence response. Gut. 1989; 30 1116-1122
31 Bruguera M, Rodicio J L, Alcazar J M. et al . Effects of different dose levels and vaccination schedules on immune response to a recombinant DNA hepatitis B vaccine in haemodialysis patients. Vaccine. 1990; 8 (Suppl) S47-S49
32 Brunetto M R, Oliveri F, Coco B. et al . Outcome of anti-HBe positive chronic hepatitis B in alpha-interferon treated and untreated patients: a long term cohort study. J Hepatol. 2002; 36 263-270
33 Buti M, Jardi R, Allende H. et al . Chronic delta hepatitis: is the prognosis worse when associated with hepatitis C virus and human immunodeficiency virus infections?. J Med Virol. 1996; 49 66-69
34 Bzowej N, Chan H L, Lai C L. et al . A randomized trial of telbivudine vs adefovir for HBeAg-positive chronic hepatitis B. Hepatology. 2006; 44 563A
35 Cacciola I, Pollicino T, Squadrito G. et al . Occult hepatitis B virus infection in patients with chronic hepatitis C liver disease. N Engl J Med. 1999; 341 22-26
36 Cardell K, Fryden A, Normann B. Intradermal hepatitis B vaccination in health care workers. Response rate and experiences from vaccination in clinical practise. Scand J Infect Dis. 1999; 31 197-200
37 Caredda F, Rossi E, d"Arminio M A. et al . Hepatitis B virus-associated coinfection and superinfection with delta agent: indistinguishable disease with different outcome. J Infect Dis. 1985; 151 925-928
38 Carlsson T, Struve J, Sonnerborg A. et al . The anti-HBs response after 2 different accelerated intradermal and intramuscular schemes for hepatitis B vaccination. Scand J Infect Dis. 1999; 31 93-95
39 Castells L, Vargas V, Rodriguez F. et al . Clinical impact and efficacy of lamivudine therapy in de novo hepatitis B infection after liver transplantation. Liver Transpl. 2002; 8 892-900
40 Castelnau C, Le G al F, Ripault M P. et al . Efficacy of peginterferon alpha-2b in chronic hepatitis delta: relevance of quantitative RT-PCR for follow-up. Hepatology. 2006; 44 728-735
41 CDC . Recombinant Hepatitis B Vaccine and the Risk of Multiple Sclerosis. Electronic Citation. 2004; , www.cdc.gov/ncidod/diseases/hepatitis/b/hbv_ms.pdf
42 Chalasani N, Smallwood G, Halcomb J. et al . Is vaccination against hepatitis B infection indicated in patients waiting for or after orthotopic liver transplantation?. Liver Transpl Surg. 1998; 4 128-132
43 Chan H L, Leung N W, Hui A Y. et al . A randomized, controlled trial of combination therapy for chronic hepatitis B: comparing pegylated interferon-alpha2b and lamivudine with lamivudine alone. Ann Intern Med. 2005; 142 240-250
44 Chan H L, Tang J L, Tam W. et al . The efficacy of thymosin in the treatment of chronic hepatitis B virus infection: a meta-analysis. Aliment Pharmacol Ther. 2001; 15 1899-1905
45 Chang T T, Gish R G, Man de R. et al . A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med. 2006; 354 1001-1010
46 Chang T T, Shiffman M, Tong M. et al . Durability of HBeAg seroconversion after adefovir dipivoxil treatment for chronic hepatitis B (CHB). Journal of Hepatology. 2004; 40 126
47 Charest A F, McDougall J, Goldstein M B. A randomized comparison of intradermal and intramuscular vaccination against hepatitis B virus in incident chronic hemodialysis patients. Am J Kidney Dis. 2000; 36 976-982
48 Chen C J, Yang H I, Su J. et al . Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA. 2006; 295 65-73
49 Chen G, Lin W, Shen F. et al . Past HBV viral load as predictor of mortality and morbidity from HCC and chronic liver disease in a prospective study. Am J Gastroenterol. 2006; 101 1797-1803
50 Chen J C, Chang M L, Lin J N. et al . Comparison of childhood hepatic malignancies in a hepatitis B hyper-endemic area. World J Gastroenterol. 2005; 11 5289-5294
51 Chen P M, Chiou T J, Fan F S. et al . Fulminant hepatitis is significantly increased in hepatitis B carriers after allogeneic bone marrow transplantation. Transplantation. 1999; 67 1425-1433
52 Chen P M, Fan S, Liu C J. et al . Changing of hepatitis B virus markers in patients with bone marrow transplantation. Transplantation. 1990; 49 708-713
53 Chen Y C, Sheen I S, Chu C M. et al . Prognosis following spontaneous HBsAg seroclearance in chronic hepatitis B patients with or without concurrent infection. Gastroenterology. 2002; 123 1084-1089
54 Cheng A L. Steroid-free chemotherapy decreases the risk of hepatitis flare-up in hepatitis B virus carriers with non-Hodgkins lymphoma. Blood. 1996; 87 1202
55 Cheng A L, Hsiung C A, Su I J. et al . Steroid-free chemotherapy decreases risk of hepatitis B virus (HBV) reactivation in HBV-carriers with lymphoma. Hepatology. 2003; 37 1320-1328
56 Chien R N, Yeh C T, Tsai S L. et al . Determinants for sustained HBeAg response to lamivudine therapy. Hepatology. 2003; 38 1267-1273
57 Christensen C, Bruden D, Livingston S. et al . Diagnostic accuracy of a fibrosis serum panel (FIBROSpect II) compared with Knodell and Ishak liver biopsy scores in chronic hepatitis C patients. J Viral Hepat. 2006; 13 652-658
58 Chu C M, Liaw Y F. Hepatitis B virus-related cirrhosis: natural history and treatment. Semin Liver Dis. 2006; 26 142-152
59 Chu C M, Yeh C T, Liaw Y F. Fulminant hepatic failure in acute hepatitis C: increased risk in chronic carriers of hepatitis B virus. Gut. 1999; 45 613-617
60 Chuang W L, Dai C Y, Chang W Y. et al . Viral interaction and responses in chronic hepatitis C and B coinfected patients with interferon-alpha plus ribavirin combination therapy. Antivir Ther. 2005; 10 125-133
61 Clark F L, Drummond M W, Chambers S. et al . Successful treatment with lamivudine for fulminant reactivated hepatitis B infection following intensive therapy for high-grade non-Hodgkin"s lymphoma. Ann Oncol. 1998; 9 385-387
62 Clemens R, Sanger R, Kruppenbacher J. et al . Booster immunization of low- and non-responders after a standard three dose hepatitis B vaccine schedule - results of a post-marketing surveillance. Vaccine. 1997; 15 349-352
63 Coates T, Wilson R, Patrick G. et al . Hepatitis B vaccines: assessment of the seroprotective efficacy of two recombinant DNA vaccines. Clin Ther. 2001; 23 392-403
64 Cockcroft D W, Gault M H. Prediction of creatinine clearance from serum creatinine. Nephron. 1976; 16 31-41
65 Cohard M, Poynard T, Mathurin P. et al . Prednisone-interferon combination in the treatment of chronic hepatitis B: direct and indirect metanalysis. Hepatology. 1994; 20 1390-1398
66 Colloredo G, Bellati G, Leandro G. et al . Quantitative analysis of IgM anti-HBc in chronic hepatitis B patients using a new “gray-zone” for the evaluation of “borderline” values. J Hepatol. 1996; 25 644-648
67 Colloredo M G, Bellati G, Leandro G. et al . Role of IgM antibody to hepatitis B core antigen in the diagnosis of hepatitis B exacerbations. Arch Virol. 1993; Suppl 8 203-211
68 Colonno R J, Rose R, Baldick C J. et al . Entecavir resistance is rare in nucleoside naive patients with hepatitis B. Hepatology. 2006; 44 1656-1665
69 Colonno R J, Rose R E, Pokornowski K. et al . Assessment at three years shows high barrier to resistance is maintained in entecavir-treated nucleoside naïve patients while resistance emergence increases over time in lamivudine refractory patients. Hepatology. 2006; 44 229A-230A
70 Confavreux C, Suissa S, Saddier P. et al . Vaccinations and the risk of relapse in multiple sclerosis. Vaccines in Multiple Sclerosis Study Group. N Engl J Med. 2001; 344 319-326
71 Cooksley W G. Treatment with interferons (including pegylated interferons) in patients with hepatitis B. Semin Liver Dis. 2004; 24 (Suppl 1] 45-53
72 Cooksley W G, Piratvisuth T, Lee S D. et al . Peginterferon alpha-2a [40 kDa): an advance in the treatment of hepatitis B e antigen-positive chronic hepatitis B. J Viral Hepat. 2003; 10 298-305
73 Cortelezzi A, Vigano M, Zilioli V R. et al . Adefovir added to lamivudine for hepatitis B recurrent infection in refractory B-cell chronic lymphocytic leukemia on prolonged therapy with Campath-1&SIXSP;H. J Clin Virol. 2006; 35 467-469
74 Cotonat T, Quiroga J A, Lopez-Alcorocho J M. et al . Pilot study of combination therapy with ribavirin and interferon alpha for the retreatment of chronic hepatitis B e antibody-positive patients. Hepatology. 2000; 31 502-506
75 Craxi A, Di Bona D, Camma C. Interferon-alpha for HBeAg-positive chronic hepatitis B. J Hepatol. 2003; 39 (Suppl 1] S99-S105
76 Crespo J, Fabrega E, Casafont F. et al . Severe clinical course of de novo hepatitis B infection after liver transplantation. Liver Transpl Surg. 1999; 5 175-183
77 Crespo J, Lozano J L, Echevarria S. et al . Influence of hepatitis C virus infection and human immunodeficiency on the natural history of chronic delta hepatitis. Rev Esp Enferm Dig. 1994; 85 185-191
78 D"Antiga L, Aw M, Atkins M. et al . Combined lamivudine/interferon-alpha treatment in “immunotolerant” children perinatally infected with hepatitis B: a pilot study. J Pediatr. 2006; 148 228-233
79 Dahmen A, Herzog-Hauff S, Bocher W O. et al . Clinical and immunological efficacy of intradermal vaccine plus lamivudine with or without interleukin-2 in patients with chronic hepatitis B. J Med Virol. 2002; 66 452-460
80 Dai M S, Chao T Y. lamivudinee therapy in HBsAg-carrying breast cancer patients undergoing chemotherapy: prophylactic or preemptive?. Breast Cancer Res Treat. 2005; 92 95-96
81 Dai M S, Wu P F, Lu J J. et al . Preemptive use of lamivudine in breast cancer patients carrying hepatitis B virus undergoing cytotoxic chemotherapy: a longitudinal study. Support Care Cancer. 2004; 12 191-196
82 Davies S E, Portmann B C, O"Grady J G. et al . Hepatic histological findings after transplantation for chronic hepatitis B virus infection, including a unique pattern of fibrosing cholestatic hepatitis. Hepatology. 2004; 13 150-157
83 De Feo T M, Poli F, Mozzi F. et al . Risk of transmission of hepatitis B virus from anti-HBC positive cadaveric organ donors: a collaborative study. Transplant Proc. 2005; 37 1238-1239
84 De Maria N, Colantoni A, Friedlander L. et al . The impact of previous HBV infection on the course of chronic hepatitis C. Am J Gastroenterol. 2000; 95 3529-3536
85 del Canho R, Grosheide P M, Mazel J A. et al . Ten-year neonatal hepatitis B vaccination program, The Netherlands, 1982 - 1992: protective efficacy and long-term immunogenicity. Vaccine. 1997; 15 1624-1630
86 del Canho R, Grosheide P M, Voogd M. et al . Immunogenicity of 20 micrograms of recombinant DNA hepatitis B vaccine in healthy neonates: a comparison of three different vaccination schemes. J Med Virol. 1993; 41 30-34
87 Delaugerre C, Marcelin A G, Thibault V. et al . Human immunodeficiency virus (HIV) Type 1 reverse transcriptase resistance mutations in hepatitis B virus (HBV)-HIV-coinfected patients treated for HBV chronic infection once daily with 10 milligrams of adefovir dipivoxil combined with lamivudine. Antimicrob Agents Chemother. 2002; 46 1586-1588
88 Dervite I, Hober D, Morel P. Acute hepatitis B in a patient with antibodies to hepatitis B surface antigen who was receiving rituximab. N Engl J Med. 2001; 344 68-69
89 Deutsch J, Wirth S. Konsensus über die Behandlung der chronischen Hepatitis B im Kindesalter. Monatsschr Kinderheilkd. 2002; 150 625-629
90 Dhedin N, Douvin C, Kuentz M. et al . Reverse seroconversion of hepatitis B after allogeneic bone marrow transplantation: a retrospective study of 37 patients with pretransplant anti-HBs and anti-HBc. Transplantation. 1998; 66 616-619
91 Di Bisceglie A, Lai C L, Gane E. et al . Telbivudine GLOBE trial: Maximal early HBV suppression is predictive of optimal two-year efficacy in nucleoside-treated hepatitis B patients. Hepatology. 2006; 44 230A-231A
92 Di Marco V, Giacchino R, Timitilli A. et al . Long-term interferon-alpha treatment of children with chronic hepatitis delta: a multicentre study. J Viral Hepat. 1996; 3 123-128
93 Di Marco V, Marzano A, Lampertico P. et al . Clinical outcome of HBeAg-negative chronic hepatitis B in relation to virological response to lamivudine. Hepatology. 2004; 40 883-891
94 Di Martino V, Lunel F, Cadranel J F. et al . Long-term effects of interferon-alpha in five HIV-positive patients with chronic hepatitis B. J Viral Hepat. 1996; 3 253-260
95 Di Martino V, Thevenot T, Boyer N. et al . Serum alanine transaminase level is a good predictor of response to interferon alpha therapy for chronic hepatitis B in human immunodeficiency virus-infected patients. Hepatology. 2000; 31 1030-1031
96 Di Martino V, Thevenot T, Colin J F. et al . Influence of HIV infection on the response to interferon therapy and the long-term outcome of chronic hepatitis B. Gastroenterology. 2002; 123 1812-1822
97 Dickson R C, Everhart J E, Lake J R. et al . Transmission of hepatitis B by transplantation of livers from donors positive for antibody to hepatitis B core antigen. The National Institute of Diabetes and Digestive and Kidney Diseases Liver Transplantation Database. Gastroenterology. 1997; 113 1668-1674
98 Dienstag J L. The role of liver biopsy in chronic hepatitis C. Hepatology. 2002; 36 S152-S160
99 Dienstag J L. The value and limitations of long-term nucleoside antiviral therapy in chronic hepatitis B. J Hepatol. 2005; 42 158-162
100 Dienstag J L, Cianciara J, Karayalcin S. et al . Durability of serologic response after lamivudine treatment of chronic hepatitis B. Hepatology. 2003; 37 748-755
101 Dienstag J L, Schiff E R, Wright T L. et al . lamivudinee as initial treatment for chronic hepatitis B in the United States. N Engl J Med. 1999; 341 1256-1263
102 Dikici B, Bosnak M, Bosnak V. et al . Combination therapy for children with chronic hepatitis B virus infection. J Gastroenterol Hepatol. 2002; 17 1087-1091
103 Dikici B, Ozgenc F, Kalayci A G. et al . Current therapeutic approaches in childhood chronic hepatitis B infection: a multicenter study. J Gastroenterol Hepatol. 2004; 19 127-133
104 Dore G J, Cooper D A, Barrett C. et al . Dual efficacy of lamivudine treatment in human immunodeficiency virus/hepatitis B virus-coinfected persons in a randomized, controlled study (CAESAR). The CAESAR Coordinating Committee. J Infect Dis. 1999; 180 607-613
105 Douglas D D, Rakela J, Wright T L. et al . The clinical course of transplantation-associated de novo hepatitis B infection in the liver transplant recipient. Liver Transpl Surg. 1997; 3 105-111
106 Duclos P. Safety of immunisation and adverse events following vaccination against hepatitis B. Expert Opin Drug Saf. 2003; 2 225-231
107 Endo T, Sakai T, Fujimoto K. et al . A possible role for lamivudine as prophylaxis against hepatitis B reactivation in carriers of hepatitis B who undergo chemotherapy and autologous peripheral blood stem cell transplantation for non-Hodgkin"s lymphoma. Bone Marrow Transplant. 2001; 27 433-436
108 Erhardt A, Blondin D, Hauck K. et al . Response to interferon alpha is hepatitis B virus genotype dependent: genotype A is more sensitive to interferon than genotype D. Gut. 2005; 54 1009-1013
109 Erhardt A, Gerlich W, Starke C. et al . Treatment of chronic hepatitis delta with pegylated interferon-alpha2b. Liver Int. 2006; 26 805-810
110 Erhardt A, Sagir A, Guillevin L. et al . Successful treatment of hepatitis B virus associated polyarteritis nodosa with a combination of prednisolone, alpha-interferon and lamivudine. J Hepatol. 2000; 33 677-683
111 Evans T G, Schiff M, Graves B. et al . The safety and efficacy of GM-CSF as an adjuvant in hepatitis B vaccination of chronic hemodialysis patients who have failed primary vaccination. Clin Nephrol. 2000; 54 138-142
112 Fabrizi F, Martin P, Dixit V. et al . HBsAg seropositive status and survival after renal transplantation: meta-analysis of observational studies. Am J Transplant. 2005; 5 2913-2921
113 Fabrizio F, Bunnapradist S, Martin P. Transplanting kidneys from donors with prior hepatitis B infection: one response to the organ shortage. J Nephrol. 2002; 15 605-613
114 Farci P, Mandas A, Coiana A. et al . Treatment of chronic hepatitis D with interferon alpha-2a. N Engl J Med. 1994; 330 88-94
115 Farci P, Roskams T, Chessa L. et al . Long-term benefit of interferon alpha therapy of chronic hepatitis D: regression of advanced hepatic fibrosis. Gastroenterology. 2004; 126 1740-1749
116 Farci P, Smedile A, Lavarini C. et al . Delta hepatitis in inapparent carriers of hepatitis B surface antigen. A disease simulating acute hepatitis B progressive to chronicity. Gastroenterology. 1983; 85 669-673
117 Farrell G C. Immunosuppression and reactivation of hepatitis B in the lamivudine era: opportunities for prevention and exploitation?. J Gastroenterol Hepatol. 1999; 14 741-744
118 Fattovich G, Boscaro S, Noventa F. et al . Influence of hepatitis delta virus infection on progression to cirrhosis in chronic hepatitis type B. J Infect Dis. 1987; 155 931-935
119 Fattovich G, Brollo L, Boscaro S. et al . Long-term effect of low dose recombinant interferon therapy in patients with chronic hepatitis B. J Hepatol. 1989; 9 331-937
120 Fattovich G, Giustina G, Christensen E. et al . Influence of hepatitis delta virus infection on morbidity and mortality in compensated cirrhosis type B. The European Concerted Action on Viral Hepatitis (Eurohep). Gut. 2000; 46 420-426
121 Firpi R J, Nelson D R. Viral hepatitis: manifestations and management strategy. Hematology Am Soc Hematol Educ Program. 2006; 375-380
122 Flink H J, Zonneveld van M, Hansen B E. et al . Treatment with Peg-interferon alpha-2b for HBeAg-positive chronic hepatitis B: HBsAg loss is associated with HBV genotype. Am J Gastroenterol. 2006; 101 297-303
123 Floreani A, Boninsegna S, Lobello S. et al . Fatal hepatic decompensation in a bone marrow transplant recipient with HBV-related cirrhosis following lamivudine withdrawal. Gastroenterol Clin Biol. 2006; 30 307-309
124 Fontana R J, Hann H W, Perrillo R P. et al . Determinants of early mortality in patients with decompensated chronic hepatitis B treated with antiviral therapy. Gastroenterology. 2002; 123 719-727
125 Fontana R J, Keeffe E B, Carey W. et al . Effect of lamivudine treatment on survival of 309 North American patients awaiting liver transplantation for chronic hepatitis B. Liver Transpl. 2002; 8 433-439
126 Fornairon S, Pol S, Legendre C. et al . The long-term virologic and pathologic impact of renal transplantation on chronic hepatitis B virus infection. Transplantation. 1996; 62 297-299
127 Fouillard L, Serfaty L, Gozlan J. Adefovir therapy for lamivudine escape and hepatitis B virus reactivation after reduced intensity conditioning allogeneic stem cell transplantation. Bone Marrow Transplant. 2006; 37 625-626
128 Fukuda R, Ishimura N, Kushiyama Y. et al . Effectiveness of interferon-alpha therapy in chronic hepatitis C is associated with the amount of interferon-alpha receptor mRNA in the liver. J Hepatol. 1997; 26 455-461
129 Fung S K, Chae H B, Fontana R J. et al . Virologic response and resistance to adefovir in patients with chronic hepatitis B. J Hepatol. 2006; 44 283-290
130 Fung S K, Wong F, Hussain M. et al . Sustained response after a 2-year course of lamivudine treatment of hepatitis B e antigen-negative chronic hepatitis B. J Viral Hepat. 2004; 11 432-438
131 Fytili P, Ciesek S, Manns M P. et al . Anti-HBc seroconversion after transplantation of anti-HBc positive nonliver organs to anti-HBc negative recipients. Transplantation. 2006; 81 808-809
132 Gan S I, Devlin S M, Scott-Douglas N W. et al . lamivudinee for the treatment of membranous glomerulopathy secondary to chronic Hepatitis B infection. Can J Gastroenterol. 2005; 19 625-629
133 Gane E, Pilmore H. Management of chronic viral hepatitis before and after renal transplantation. Transplantation. 2002; 74 427-437
134 Ganem D, Prince A M. Hepatitis B virus infection - natural history and clinical consequences. N Engl J Med. 2004; 350 1118-1129
135 Garripoli A, Di Marco V, Cozzolongo R. et al . Ribavirin treatment for chronic hepatitis D: a pilot study. Liver. 1994; 14 154-157
136 Gaudin J L, Trepo C. Therapy of chronic delta hepatitis with alpha- and beta-interferon. Prog Clin Biol Res. 1993; 382 345-352
137 Geier M R, Geier D A. Immunologic reactions and hepatitis B vaccine. Ann Intern Med. 2001; 134 1155
138 Gerlich W H, Thomssen R. Terminology, structure and laboratory diagnosis of hepatitis viruses. Bircher J, Benhamou JP, McIntyre N, Rizetto M, Rhodes J Oxford Textbook of Clinical Hepatology Oxford; Oxford University press 1999: 828-869
139 Ghany M G, Ayola B, Villamil F G. et al . Hepatitis B virus S mutants in liver transplant recipients who were reinfected despite hepatitis B immune globulin prophylaxis. Hepatology. 1998; 27 213-222
140 Gigliotti A R, Fioredda F, Giacchino R. Hepatitis B and C infection in children undergoing chemotherapy or bone marrow transplantation. J Pediatr Hematol Oncol. 2003; 25 184-192
141 Girard M. Autoimmune hazards of hepatitis B vaccine. Autoimmun Rev. 2005; 4 96-100
142 Gish R G, Chang T T, Man R A. et al . Entecavir results in substantial virologic and biochemical improvement and HBeAg seroconversion through 96 weeks of treatment in HBeAg(+) chronic hepatitis B patients (study ETV-022]. Hepatology. 2005; 42 267A-268A
143 Govindarajan de S, Chin K P, Redeker A G. et al . Fulminant B viral hepatitis: role of delta agent. Gastroenterology. 1984; 86 1417-1420
144 Gregorio G V, Jara P, Hierro L. et al . Lymphoblastoid interferon alpha with or without steroid pretreatment in children with chronic hepatitis B: a multicenter controlled trial. Hepatology. 1996; 23 700-707
145 Grob P, Jilg W, Bornhak H. et al . Serological pattern “anti-HBc alone”: report on a workshop. J Med Virol. 2000; 62 450-455
146 Gunsar F, Akarca U S, Ersoz G. et al . Two-year interferon therapy with or without ribavirin in chronic delta hepatitis. Antivir Ther. 2005; 10 721-726
147 Hadler S C, Alcala d M, Rivero D. et al . Epidemiology and long-term consequences of hepatitis delta virus infection in the Yucpa Indians of Venezuela. Am J Epidemiol. 1992; 136 1507-1516
148 Hadler S C, Monzon de M, Ponzetto A. et al . Delta virus infection and severe hepatitis. An epidemic in the Yucpa Indians of Venezuela. Ann Intern Med. 1984; 100 339-344
149 Hadler S C, Francis D P, Maynard J E. et al . Long-term immunogenicity and efficacy of hepatitis B vaccine in homosexual men. N Engl J Med. 1986; 315 209-214
150 Hadler S C, Judson F N, O"Malley P M. et al . Outcome of hepatitis B virus infection in homosexual men and its relation to prior human immunodeficiency virus infection. J Infect Dis. 1991; 163 454-459
151 Hadziyannis S J, Papatheodoridis G V, Dimou E. et al . Efficacy of long-term lamivudine monotherapy in patients with hepatitis B e antigen-negative chronic hepatitis B. Hepatology. 2000; 32 847-851
152 Hadziyannis S J, Sevastianos V, Rapti I. et al . Sustained biochemical and virological remission after discontinuation of 4 to 5 years of adefovir dipivoxil treatment in HBeAg-negative chronic hepatitis B. Hepatology. 2006; 44 231A
153 Hadziyannis S J, Tassopoulos N C, Heathcote E J. et al . Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B. N Engl J Med. 2005; 352 2673-2681
154 Hadziyannis S J, Tassopoulos N C, Heathcote E J. et al . Long-term Therapy With Adefovir Dipivoxil for HBeAg-Negative Chronic Hepatitis B for up to 5 Years. Gastroenterology. 2006; 131 1743-1751
155 Hadziyannis S J, Tassopoulos N C, Heathcote E J. et al . Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B. N Engl J Med. 2003; 348 800-807
156 Hartman C, Berkowitz D, Eshach-Adiv O. et al . Long-term lamivudine therapy for chronic hepatitis B infection in children unresponsive to interferon. J Pediatr Gastroenterol Nutr. 2006; 43 494-498
157 Hartwig M G, Patel V, Palmer S M. et al . Hepatitis B core antibody positive donors as a safe and effective therapeutic option to increase available organs for lung transplantation. Transplantation. 2005; 80 320-325
158 Hasselhorn H M, Kralj N, Hofmann F. et al . Non- and low-response after preventive hepatitis B vaccination. Gesundheitswesen. 1997; 59 321-328
159 Heintges T, Petry W, Kaldewey M. et al . Combination therapy of active HBsAg vaccination and interferon-alpha in interferon-alpha nonresponders with chronic hepatitis B. Dig Dis Sci. 2001; 46 901-906
160 Henderson E A, Louie T J, Ramotar K. et al . Comparison of higher-dose intradermal hepatitis B vaccination to standard intramuscular vaccination of healthcare workers. Infect Control Hosp Epidemiol. 2000; 21 264-269
161 Hernan M A, Jick S S, Olek M J. et al . Recombinant hepatitis B vaccine and the risk of multiple sclerosis: a prospective study. Neurology. 2004; 63 838-842
162 Hillis W D, Hillis A, Walker W G. Hepatitis B surface antigenemia in renal transplant recipients. Increased mortality risk. JAMA. 1979; 242 329-332
163 Hoff J, Bani-Sadr F, Gassin M. et al . Evaluation of chronic hepatitis B virus (HBV) infection in coinfected patients receiving lamivudine as a component of anti-human immunodeficiency virus regimens. Clin Infect Dis. 2001; 32 963-969
164 Hom X, Little N R, Gardner S D. et al . Predictors of virologic response to lamivudinee treatment in children with chronic hepatitis B infection. Pediatr Infect Dis J. 2004; 23 441-445
165 Hoofnagle J H, Seeff L B. Peginterferon and ribavirin for chronic hepatitis C. N Engl J Med. 2006; 355 2444-2451
166 Housset C, Pol S, Carnot F. et al . Interactions between human immunodeficiency virus-1, hepatitis delta virus and hepatitis B virus infections in 260 chronic carriers of hepatitis B virus. Hepatology. 1992; 15 578-583
167 Hsu Y S, Chien R N, Yeh C T. et al . Long-term outcome after spontaneous HBeAg seroconversion in patients with chronic hepatitis B. Hepatology. 2002; 35 1522-1527
168 Hui A Y, Chan H L, Cheung A Y. et al . Systematic review: treatment of chronic hepatitis B virus infection by pegylated interferon. Aliment Pharmacol Ther. 2005; 22 519-528
169 Hui C K, Cheung W W, Au W Y. et al . Hepatitis B reactivation after withdrawal of pre-emptive lamivudine in patients with haematological malignancy on completion of cytotoxic chemotherapy. Gut. 2005; 54 1597-1603
170 Hui C K, Cheung W W, Zhang H Y. et al . Kinetics and risk of de novo hepatitis B infection in HBsAg-negative patients undergoing cytotoxic chemotherapy. Gastroenterology. 2006; 131 59-68
171 Hui C K, Lau E, Wu H. et al . Fibrosis progression in chronic hepatitis C patients with occult hepatitis B co-infection. J Clin Virol. 2006; 35 185-192
172 Huo T I, Wu J C, Lai C R. et al . Comparison of clinico-pathological features in hepatitis B virus-associated hepatocellular carcinoma with or without hepatitis D virus superinfection. J Hepatol. 1996; 25 439-444
173 Iannitto E, Minardi V, Calvaruso G. et al . Hepatitis B virus reactivation and alemtuzumab therapy. Eur J Haematol. 2005; 74 254-258
174 Idilman R, Arat M, Soydan E. et al . lamivudinee prophylaxis for prevention of chemotherapy-induced hepatitis B virus reactivation in hepatitis B virus carriers with malignancies. J Viral Hepat. 2004; 11 141-147
175 Idilman R, Colantoni A, De Maria N. et al . Impaired antibody response rates after high dose short interval hepatitis B virus vaccination of immunosuppressed individuals. Hepatogastroenterology. 2003; 50 217-221
176 Ikeda K, Shiga Y, Takahashi A. et al . Fatal hepatitis B virus reactivation in a chronic myeloid leukemia patient during imatinib mesylate treatment. Leuk Lymphoma. 2006; 47 155-157
177 Ilan Y, Ashur Y, Tur-Kaspa R. et al . Chronic hepatitis C virus infection with exposure to hepatitis B virus. Isr J Med Sci. 1994; 30 259-263
178 Iloeje U H, Yang H I, Su J. et al . Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology. 2006; 130 678-686
179 Imbert-Bismut F, Ratziu V, Pieroni L. et al . Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study. Lancet. 2001; 357 1069-1075
180 Institute of Medicine - Report . Hepatitis B vaccine and demyelinating neurological disorders. Electronic Citation. 2002; , www.cdc.gov/nip/vaccine/hep/hepb/iom.htm
181 Iwai K, Tashima M, Itoh M. et al . Fulminant hepatitis B following bone marrow transplantation in an HBsAg-negative, HBsAb-positive recipient, reactivation of dormant virus during the immunosuppressive period. Bone Marrow Transplant. 2000; 25 105-108
182 Jang J W, Choi J Y, Bae S H. et al . Transarterial chemo-lipiodolization can reactivate hepatitis B virus replication in patients with hepatocellular carcinoma. J Hepatol. 2004; 41 427-435
183 Jang J W, Choi J Y, Bae S H. et al . A randomized controlled study of preemptive lamivudine in patients receiving transarterial chemo-lipiodolization. Hepatology. 2006; 43 233-240
184 Janssen H L, Zonneveld van M, Senturk H. et al . Pegylated interferon alpha-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial. Lancet. 2005; 365 123-129
185 Janssen H L, Zonneveld van M, Nunen A B. et al . Polyarteritis nodosa associated with hepatitis B virus infection. The role of antiviral treatment and mutations in the hepatitis B virus genome. Eur J Gastroenterol Hepatol. 2004; 16 801-807
186 Jardi van R, Rodriguez F, Buti M. et al . Role of hepatitis B, C, and D viruses in dual and triple infection: influence of viral genotypes and hepatitis B precore and basal core promoter mutations on viral replicative interference. Hepatology. 2001; 34 404-410
187 Jilg W, Hottentrager B, Weinberger K. et al . Prevalence of markers of hepatitis B in the adult German population. J Med Virol. 2001; 63 96-102
188 Jilg W, Schmidt M, Deinhardt F. Four-year experience with a recombinant hepatitis B vaccine. Infection. 1989; 17 70-76
189 Jilg W, Schmidt M, Deinhardt F. Inoculation failure following hepatitis B vaccination. The effect of additional vaccinations. Dtsch Med Wochenschr. 1990; 115 1545-1548
190 Jonas M M, Mizerski J, Badia I B. et al . Clinical trial of lamivudine in children with chronic hepatitis B. N Engl J Med. 2002; 346 1706-1713
191 Kanaan N, Horsmans Y, Goffin E. lamivudinee for nephrotic syndrome related to hepatitis B virus (HBV) infection. Clin Nephrol. 2006; 65 208-210
192 Kanwal F, Farid M, Martin P. et al . Treatment alternatives for hepatitis B cirrhosis: a cost-effectiveness analysis. Am J Gastroenterol. 2006; 101 2076-2089
193 Kapoor D, Aggarwal S R, Singh N P. et al . Granulocyte-macrophage colony-stimulating factor enhances the efficacy of hepatitis B virus vaccine in previously unvaccinated haemodialysis patients. J Viral Hepat. 1999; 6 405-409
194 Kapoor D, Guptan R C, Wakil S M. et al . Beneficial effects of lamivudine in hepatitis B virus-related decompensated cirrhosis. J Hepatol. 2000; 33 308-312
195 Kelly D. Viral hepatitis in children. Adv Exp Med Biol. 2004; 549 83-90
196 Kempinska A, Kwak E J, Angel J B. Reactivation of hepatitis B infection following allogeneic bone marrow transplantation in a hepatitis B-immune patient: case report and review of the literature. Clin Infect Dis. 2005; 41 1277-1282
197 Kim K H, Ahn S H, Chung H Y. et al . Hepatitis B virus infection after renal transplantation in the presence of antibody to hepatitis B surface antigen immunity. J Gastroenterol Hepatol. 2004; 19 847-53
198 Knoll A, Boehm S, Hahn J. et al . Reactivation of resolved hepatitis B virus infection after allogeneic haematopoietic stem cell transplantation. Bone Marrow Transplant. 2004; 33 925-929
199 Knoll A, Hartmann A, Hamoshi H. et al . Serological pattern “anti-HBc alone”: characterization of 552 individuals and clinical significance. World J Gastroenterol. 2006; 12 1255-1260
200 Kohmoto M, Enomoto M, Tamori A. et al . Quantitative detection of hepatitis B surface antigen by chemiluminescent microparticle immunoassay during lamivudine treatment of chronic hepatitis B virus carriers. J Med Virol. 2005; 75 235-239
201 Kondili L A, Osman H, Mutimer D. The use of lamivudine for patients with acute hepatitis B (a series of cases). J Viral Hepat. 2004; 11 427-431
202 Konopnicki D, Mocroft A, Wit de S. et al . Hepatitis B and HIV: prevalence, AIDS progression, response to highly active antiretroviral therapy and increased mortality in the EuroSIDA cohort. AIDS. 2005; 19 593-601
203 Korenman J, Baker B, Waggoner J. et al . Long-term remission of chronic hepatitis B after alpha-interferon therapy. Ann Intern Med. 1991; 114 629-634
204 Kruger M, Boker K H, Zeidler H. et al . Treatment of hepatitis B-related polyarteritis nodosa with famciclovir and interferon alpha-2b. J Hepatol. 1997; 26 935-939
205 Kumagai K, Takagi T, Nakamura S. et al . Hepatitis B virus carriers in the treatment of malignant lymphoma: an epidemiological study in Japan. Ann Oncol. 1997; 8 (Suppl 1] 107-109
206 Kumar M, Satapathy S, Monga R. et al . A randomized controlled trial of lamivudine to treat acute hepatitis B. Hepatology. 2007; 45 97-101
207 Kuo A, Dienstag J L, Chung R T. Tenofovir disoproxil fumarate for the treatment of lamivudine-resistant hepatitis B. Clin Gastroenterol Hepatol. 2004; 2 266-272
208 Lackner H, Moser A, Benesch M. et al . Serological and molecular response on combined antiviral treatment in children with chronic hepatitis B after pediatric malignancy. J Clin Virol. 2002; 25 (Suppl 3] S73-S79
209 Lai C L, Chien R N, Leung N W. et al . A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis lamivudinee Study Group. N Engl J Med. 1998; 339 61-68
210 Lai C L, Dienstag J, Schiff E. et al . Prevalence and clinical correlates of YMDD variants during lamivudine therapy for patients with chronic hepatitis B. Clin Infect Dis. 2003; 36 687-696
211 Lai C L, Gane E, Hsu C W. et al . Two-year results from the GLOBE trial in patients with hepatitis B: greater clinical and antiviral efficacy for telbivudine vs lamivudine. Hepatology. 2006; 44 222A
212 Lai C L, Gane E, Liaw Y F. et al . Telbivudine (LdT) vs. lamivudine for chronic hepatitis B: First-year results from the international phase III globe trial. Hepatology. 2005; 42 748A
213 Lai C L, Leung N, Teo E K. et al . A 1-year trial of telbivudine, lamivudine, and the combination in patients with hepatitis B e antigen-positive chronic hepatitis B. Gastroenterology. 2005; 129 528-536
214 Lai C L, Shouval D, Lok A S. et al . Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N Engl J Med. 2006; 354 1011-1020
215 Lampertico P, Del Ninno E, Vigano M. et al . Long-term suppression of hepatitis B e antigen-negative chronic hepatitis B by 24-month interferon therapy. Hepatology. 2003; 37 756-763
216 Lampertico P, Marzano A, Levrero M. et al . Adefovir and lamivudine combination therapy is superior to adefovir monotherapy for lamivudine-resistant patients with HBeAg-negative chronic hepatitis B. Hepatology. 2006; 44 693A-694A
217 Lampertico P, Vigano M, Manenti E. et al . Adefovir rapidly suppresses hepatitis B in HBeAg-negative patients developing genotypic resistance to lamivudine. Hepatology. 2005; 42 1414-1419
218 Lang M, Neumann U, Kahl A. et al . Long-term outcome of 27 patients after combined liver-kidney transplantation. Transplant Proc. 2001; 33 1440-1441
219 Lau D T, Doo E, Park Y. et al . lamivudinee for chronic delta hepatitis. Hepatology. 1999; 30 546-549
220 Lau D T, Everhart J, Kleiner D E. et al . Long-term follow-up of patients with chronic hepatitis B treated with interferon alpha. Gastroenterology. 1997; 113 1660-1667
221 Lau D T, Kleiner D E, Park Y. et al . Resolution of chronic delta hepatitis after 12 years of interferon alpha therapy. Gastroenterology. 1999; 117 1229-1233
222 Lau G K, He M L, Fong D Y. et al . Preemptive use of lamivudine reduces hepatitis B exacerbation after allogeneic hematopoietic cell transplantation. Hepatology. 2002; 36 702-709
223 Lau G K, Liang R, Chiu E K. et al . Hepatic events after bone marrow transplantation in patients with hepatitis B infection: a case controlled study. Bone Marrow Transplant. 1997; 19 795-799
224 Lau G K, Lok A S, Liang R H. et al . Clearance of hepatitis B surface antigen after bone marrow transplantation: role of adoptive immunity transfer. Hepatology. 1997; 25 1497-1501
225 Lau G K, Piratvisuth T, Luo K X. et al . Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med. 2005; 352 2682-2695
226 Lau G K, Suri D, Liang R. et al . Resolution of chronic hepatitis B and anti-HBs seroconversion in humans by adoptive transfer of immunity to hepatitis B core antigen. Gastroenterology. 2002; 122 614-624
227 Lau G K, Yiu H H, Fong D Y. et al . Early is superior to deferred preemptive lamivudine therapy for hepatitis B patients undergoing chemotherapy. Gastroenterology. 2003; 125 1742-1749
228 Lau J Y, Smith H M, Chaggar K. et al . Significance of IgM anti-hepatitis D virus (HDV) in chronic HDV infection. J Med Virol. 1991; 33 273-276
229 Laubscher B, Gehri M, Roulet M. et al . Survival of infantile fulminant hepatitis B and treatment with lamivudinee. J Pediatr Gastroenterol Nutr. 2005; 40 518-520
230 Lavanchy D. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J Viral Hepat. 2004; 11 97-107
231 Law J K, Ho J K, Hoskins P J. et al . Fatal reactivation of hepatitis B post-chemotherapy for lymphoma in a hepatitis B surface antigen-negative, hepatitis B core antibody-positive patient: potential implications for future prophylaxis recommendations. Leuk Lymphoma. 2005; 46 1085-1089
232 Le Gal F, Gordien E, Affolabi D. et al . Quantification of hepatitis delta virus RNA in serum by consensus real-time PCR indicates different patterns of virological response to interferon therapy in chronically infected patients. J Clin Microbiol. 2005; 43 2363-2369
233 Leaw S J, Yen C J, Huang W T. et al . Preemptive use of interferon or lamivudine for hepatitis B reactivation in patients with aggressive lymphoma receiving chemotherapy. Ann Hematol. 2004; 83 270-275
234 Lee C, Gong Y, Brok J. et al . Effect of hepatitis B immunisation in newborn infants of mothers positive for hepatitis B surface antigen: systematic review and meta-analysis. BMJ. 2006; 332 328-336
235 Lee C, Gong Y, Brok J. et al . Hepatitis B immunisation for newborn infants of hepatitis B surface antigen-positive mothers. Cochrane Database Syst Rev. 2006; CD004790
236 Lee G W, Ryu M H, Lee J L. et al . The prophylactic use of lamivudine can maintain dose-intensity of adriamycin in hepatitis-B surface antigen (HBs Ag)-positive patients with Non-Hodgkin"s lymphoma who receive cytotoxic chemotherapy. J Korean Med Sci. 2003; 18 849-854
237 Lee K M, Cho S W, Kim S W. et al . Effect of virological response on post-treatment durability of lamivudine-induced HBeAg seroconversion. J Viral Hepat. 2002; 9 208-212
238 Lee W C, Wu M J, Cheng C H. et al . lamivudinee is effective for the treatment of reactivation of hepatitis B virus and fulminant hepatic failure in renal transplant recipients. Am J Kidney Dis. 2001; 38 1074-1081
239 Lee Y S, Suh D J, Lim Y S. et al . Increased risk of adefovir resistance in patients with lamivudine-resistant chronic hepatitis B after 48 weeks of adefovir dipivoxil monotherapy. Hepatology. 2006; 43 1385-1391
240 Li Y H, He Y F, Jiang W Q. et al . lamivudinee prophylaxis reduces the incidence and severity of hepatitis in hepatitis B virus carriers who receive chemotherapy for lymphoma. Cancer. 2006; 106 1320-1325
241 Liao S S, Li R C, Li H. et al . Long-term efficacy of plasma-derived hepatitis B vaccine: a 15-year follow-up study among Chinese children. Vaccine. 1999; 17 2661-2666
242 Liaw Y F. Prevention and surveillance of hepatitis B virus-related hepatocellular carcinoma. Semin Liver Dis. 2005; 25 (Suppl 1] 40-47
243 Liaw Y F, Chen Y C, Sheen I S. et al . Impact of acute hepatitis C virus superinfection in patients with chronic hepatitis B virus infection. Gastroenterology. 2004; 126 1024-1029
244 Liaw Y F, Chien R N, Yeh C T. No benefit to continue lamivudine therapy after emergence of YMDD mutations. Antivir Ther. 2004; 9 257-262
245 Liaw Y F, Leung N W, Chang T T. et al . Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Asia Hepatitis lamivudinee Study Group. Gastroenterology. 2000; 119 172-180
246 Liaw Y F, Sung J J, Chow W C. et al . lamivudinee for patients with chronic hepatitis B and advanced liver disease. N Engl J Med. 2004; 351 1521-1531
247 Liaw Y F, Tsai S L, Sheen I S. et al . Clinical and virological course of chronic hepatitis B virus infection with hepatitis C and D virus markers. Am J Gastroenterol. 1998; 93 354-359
248 Lim L L, Wai C T, Lee Y M. et al . Prophylactic lamivudine prevents hepatitis B reactivation in chemotherapy patients. Aliment Pharmacol Ther. 2002; 16 1939-1944
249 Lim S G, Krastev Z, Ng T M. et al . Randomized, double-blind study of emtricitabine (FTC) plus clevudine versus FTC alone in treatment of chronic hepatitis B. Antimicrob Agents Chemother. 2006; 50 1642-1648
250 Lin C C, Chen C L, Concejero A. et al . Active immunization to prevent de novo hepatitis B virus infection in pediatric live donor liver recipients. Am J Transplant. 2007; 7 195-200
251 Lin S M, Sheen I S, Chien R N. et al . Long-term beneficial effect of interferon therapy in patients with chronic hepatitis B virus infection. Hepatology. 1999; 29 971-975
252 Lin S M, Yu M L, Lee C M. et al . Interferon therapy in HBeAg positive chronic hepatitis reduces progression to cirrhosis and hepatocellular carcinoma. J Hepatol. 2007; 46 45-52
253 Lo C M, Liu C L, Lau G K. et al . Liver transplantation for chronic hepatitis B with lamivudine-resistant YMDD mutant using add-on adefovir dipivoxil plus lamivudine. Liver Transpl. 2005; 11 807-813
254 Locarnini S. Molecular virology and the development of resistant mutants: implications for therapy. Semin Liver Dis. 2005; 25 (Suppl 1] 9-19
255 Locarnini S, Hatzakis A, Heathcote J. et al . Management of antiviral resistance in patients with chronic hepatitis B. Antivir Ther. 2004; 9 679-693
256 Lok A S, Lai C L. A longitudinal follow-up of asymptomatic hepatitis B surface antigen-positive Chinese children. Hepatology. 1988; 8 1130-1133
257 Lok A S, Lai C L, Leung N. et al . Long-term safety of lamivudine treatment in patients with chronic hepatitis B. Gastroenterology. 2003; 125 1714-1722
258 Lok A S, Liang R H, Chiu E K. et al . Reactivation of hepatitis B virus replication in patients receiving cytotoxic therapy. Report of a prospective study. Gastroenterology. 1991; 100 182-188
259 Lok A S, McMahon B J. AASLD Practice Guidelines. Chronic hepatitis B: update of therapeutic guidelines. Rom J Gastroenterol. 2004; 13 150-154
260 Looney R J, Hasan M S, Coffin D. et al . Hepatitis B immunization of healthy elderly adults: relationship between naive CD 4 + T cells and primary immune response and evaluation of GM-CSF as an adjuvant. J Clin Immunol. 2001; 21 30-36
261 Lucey M R, Graham D M, Martin P. et al . Recurrence of hepatitis B and delta hepatitis after orthotopic liver transplantation. Gut. 1992; 33 1390-1396
262 Madejon A, Cotonat T, Bartolome J. et al . Treatment of chronic hepatitis D virus infection with low and high doses of interferon-alpha 2a: utility of polymerase chain reaction in monitoring antiviral response. Hepatology. 1994; 19 1331-1336
263 Manesis E K, Hadziyannis S J. Interferon alpha treatment and retreatment of hepatitis B e antigen-negative chronic hepatitis B. Gastroenterology. 2001; 121 101-109
264 Manns M P, Wedemeyer H, Cornberg M. Treating viral hepatitis C: efficacy, side effects, and complications. Gut. 2006; 55 1350-1359
265 Manzarbeitia C, Reich D J, Ortiz J A. et al . Safe use of livers from donors with positive hepatitis B core antibody. Liver Transpl. 2002; 8 556-561
266 Marangi A L, Giordano R, Montanaro A. et al . Hepatitis B virus infection in chronic uremia: long-term follow-up of a two-step integrated protocol of vaccination. Am J Kidney Dis. 1994; 23 537-542
267 Marcellin P, Boyer N, Colin J F. et al . Recombinant alpha interferon for chronic hepatitis B in anti-HIV positive patients receiving zidovudine. Gut. 1993; 34 S106
268 Marcellin P, Chang T T, Lim S G. et al . Long-term efficacy and safety of adefovir dipivoxil for the treatment of HBeAg-positive chronic hepatitis B (CHB) patients. Hepatology. 2006; 44 548A
269 Marcellin P, Chang T T, Lim S G. et al . Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N Engl J Med. 2003; 348 808-816
270 Marcellin P, Lau G K, Bonino F. et al . Peginterferon alpha-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. N Engl J Med. 2004; 351 1206-1217
271 Margreiter R, Kramar R, Huber C. et al . Combined liver and kidney transplantation. Lancet. 1984; 1 1077-1078
272 Maria Elzbieta S L, Marek L D. Histological outcome of chronic hepatitis B in children treated with interferon alpha. World J Gastroenterol. 2005; 11 7179-7182
273 Markovic S, Drozina G, Vovk M. et al . Reactivation of hepatitis B but not hepatitis C in patients with malignant lymphoma and immunosuppressive therapy. A prospective study in 305 patients. Hepatogastroenterology. 1999; 46 2925-2930
274 Markowitz J S, Martin P, Conrad A J. et al . Prophylaxis against hepatitis B recurrence following liver transplantation using combination lamivudine and hepatitis B immune globulin. Hepatology. 1998; 28 585-589
275 Martinez E, Blanco J L, Arnaiz J A. et al . Hepatotoxicity in HIV-1-infected patients receiving nevirapine-containing antiretroviral therapy. AIDS. 2001; 15 1261-1268
276 Marusawa H, Chiba T. How can we prevent viral reactivation in liver transplantation from donors with latent hepatitis B virus infection?. J Gastroenterol. 2001; 36 212-213
277 Marzano A, Salizzoni M, Debernardi-Venon W. et al . Prevention of hepatitis B virus recurrence after liver transplantation in cirrhotic patients treated with lamivudine and passive immunoprophylaxis. J Hepatol. 2001; 34 903-910
278 Mason W S, Taylor J M. Liver transplantation: a model for the transmission of hepatitis delta virus. Gastroenterology. 1991; 101 1741-1743
279 Mast E E, Weinbaum C M, Fiore A E. et al . A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP) Part II: immunization of adults. MMWR Recomm Rep. 2006; 55 1-33
280 Mathurin P, Mouquet C, Poynard T. et al . Impact of hepatitis B and C virus on kidney transplantation outcome. Hepatology. 1999; 29 257-263
281 Mathurin P, Thibault V, Kadidja K. et al . Replication status and histological features of patients with triple (B, C, D) and dual (B, C) hepatic infections. J Viral Hepat. 2000; 7 15-22
282 McDonald J A, Harris S, Waters J A. et al . Effect of human immunodeficiency virus (HIV) infection on chronic hepatitis B hepatic viral antigen display. J Hepatol. 1987; 4 337-342
283 McMahon B J, Alward W L, Hall D B. et al . Acute hepatitis B virus infection: relation of age to the clinical expression of disease and subsequent development of the carrier state. J Infect Dis. 1985; 151 599-603
284 Mertens T, Haller O A, Klenk H D. Diagnostik und Therapie von Viruskrankheiten: Leitlinien der Gesellschaft für Virologie. Munich; Urban und Fischer-Verlag 2004
285 Mettang T, Schenk U, Thomas S. et al . Low-dose intradermal versus intramuscular hepatitis B vaccination in patients with end-stage renal failure. A preliminary study. Nephron. 1996; 72 192-196
286 Miro J M, Laguno M, Moreno A. et al . Management of end stage liver disease (ESLD): what is the current role of orthotopic liver transplantation (OLT)?. J Hepatol. 2006; 44 S140-S145
287 Mitsui T, Iwano K, Suzuki S. et al . Combined hepatitis B immune globulin and vaccine for postexposure prophylaxis of accidental hepatitis B virus infection in hemodialysis staff members: comparison with immune globulin without vaccine in historical controls. Hepatology. 1989; 10 324-327
288 Mitwalli A. Responsiveness to hepatitis B vaccine in immunocompromised patients by doubling the dose scheduling. Nephron. 1996; 73 417-420
289 Monteyne P, Andre F E. Is there a causal link between hepatitis B vaccination and multiple sclerosis?. Vaccine. 2000; 18 1994-2001
290 Mutchnick M G, Lindsay K L, Schiff E R. et al . Thymosin alpha1 treatment of chronic hepatitis B: results of a phase III multicentre, randomized, double-blind and placebo-controlled study. J Viral Hepat. 1999; 6 397-403
291 Myers R P, Tainturier M H, Ratziu V. et al . Prediction of liver histological lesions with biochemical markers in patients with chronic hepatitis B. J Hepatol. 2003; 39 222-230
292 Nagamatsu H, Itano S, Nagaoka S. et al . Prophylactic lamivudine administration prevents exacerbation of liver damage in HBe antigen positive patients with hepatocellular carcinoma undergoing transhepatic arterial infusion chemotherapy. Am J Gastroenterol. 2004; 99 2369-2375
293 Nagamatsu H, Kumashiro R, Itano S. et al . Investigation of associating factors in exacerbation of liver damage after chemotherapy in patients with HBV-related HCC. Hepatol Res. 2003; 26 293-301
294 Nakamura Y, Motokura T, Fujita A. et al . Severe hepatitis related to chemotherapy in hepatitis B virus carriers with hematologic malignancies. Survey in Japan, 1987 - 1991. Cancer. 1996; 78 2210-2215
295 Neff G W, Bonham A, Tzakis A G. et al . Orthotopic liver transplantation in patients with human immunodeficiency virus and end-stage liver disease. Liver Transpl. 2003; 9 239-247
296 Neff G W, Nery J, Lau D T. et al . Tenofovir therapy for lamivudine resistance following liver transplantation. Ann Pharmacother. 2004; 38 1999-2004
297 Neumann U P, Lang M, Moldenhauer A. et al . Significance of a T-lymphocytotoxic crossmatch in liver and combined liver-kidney transplantation. Transplantation. 2001; 71 1163-1168
298 Ni Y H, Huang F C, Wu T C. et al . lamivudinee treatment in maternally transmitted chronic hepatitis B virus infection patients. Pediatr Int. 2005; 47 372-377
299 Niederau C, Heintges T, Lange S. et al . Long-term follow-up of HBeAg-positive patients treated with interferon alpha for chronic hepatitis B. N Engl J Med. 1996; 334 1422-1427
300 Niro G A, Ciancio A, Gaeta G B. et al . Pegylated interferon alpha-2b as monotherapy or in combination with ribavirin in chronic hepatitis delta. Hepatology. 2006; 44 713-720
301 Ohtsu T, Sai T, Oka M. et al . Activation of hepatitis B virus infection by chemotherapy containing glucocorticoid in hepatitis B virus carriers with hematologic malignancies. Jpn J Clin Oncol. 1991; 21 360-365
302 Olausson M, Mjornstedt L, Norden G. et al . Successful combined partial auxiliary liver and kidney transplantation in highly sensitized cross-match positive recipients. Am J Transplant. 2007; 7 130-136
303 Ollenschlager G, Kopp I, Lelgemann M. et al . The German program for disease management guidelines. Background, methods, and development process. Med Klin. 2006; 101 840-845
304 Onozawa M, Hashino S, Izumiyama K. et al . Progressive disappearance of anti-hepatitis B surface antigen antibody and reverse seroconversion after allogeneic hematopoietic stem cell transplantation in patients with previous hepatitis B virus infection. Transplantation. 2005; 79 616-619
305 Ozgenc F, Arikan C, Sertoz R Y. et al . Effect of long-term lamivudine in chronic hepatitis B virus-infected children. Antivir Ther. 2004; 9 729-732
306 Ozguroglu M, Bilici A, Turna H. et al . Reactivation of hepatitis B virus infection with cytotoxic therapy in non-Hodgkin"s lymphoma. Med Oncol. 2004; 21 67-72
307 Palmer D R, Perry K R, Mortimer P P. et al . Variation in the sensitivity of HBsAg screening kits. Transfus Med. 1996; 6 311-317
308 Papatheodoridis G V, Dimou E, Laras A. et al . Course of virologic breakthroughs under long-term lamivudine in HBeAg-negative precore mutant HBV liver disease. Hepatology. 2002; 36 219-226
309 Papatheodoridis G V, Manesis E, Hadziyannis S J. The long-term outcome of interferon-alpha treated and untreated patients with HBeAg-negative chronic hepatitis B. J Hepatol. 2001; 34 306-313
310 Park J W, Park K W, Cho S H. et al . Risk of hepatitis B exacerbation is low after transcatheter arterial chemoembolization therapy for patients with HBV-related hepatocellular carcinoma: report of a prospective study. Am J Gastroenterol. 2005; 100 2194-2200
311 Pastore G, Santantonio T, Monno L. et al . Permanent inhibition of viral replication induced by low dosage of human leukocyte interferon in patients with chronic hepatitis B. Hepatogastroenterology. 1988; 35 57-61
312 Perrillo R, Hann H W, Mutimer D. et al . Adefovir dipivoxil added to ongoing lamivudine in chronic hepatitis B with YMDD mutant hepatitis B virus. Gastroenterology. 2004; 126 81-90
313 Perrillo R P, Lai C L, Liaw Y F. et al . Predictors of HBeAg loss after lamivudine treatment for chronic hepatitis B. Hepatology. 2002; 36 186-194
314 Perrillo R P, Wright T, Rakela J. et al . A multicenter United States-Canadian trial to assess lamivudine monotherapy before and after liver transplantation for chronic hepatitis B. Hepatology. 2001; 33 424-432
315 Persico M, De Marino F, Russo G D. et al . Efficacy of lamivudine to prevent hepatitis reactivation in hepatitis B virus-infected patients treated for non-Hodgkin lymphoma. Blood. 2002; 99 724-725
316 Perz J F, Armstrong G L, Farrington L A. et al . The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J Hepatol. 2006; 45 529-538
317 Peters M G, Andersen J, Lynch P. et al . Randomized controlled study of tenofovir and adefovir in chronic hepatitis B virus and HIV infection: ACTG A 5127. Hepatology. 2006; 44 1110-1116
318 Peters M G, Hann H H, Martin P. et al . Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B. Gastroenterology. 2004; 126 91-101
319 Pineda J A, Romero-Gomez M, Diaz-Garcia F. et al . HIV coinfection shortens the survival of patients with hepatitis C virus-related decompensated cirrhosis. Hepatology. 2005; 41 779-789
320 Pirson Y, Alexandre G P, Ypersele C. Long-term effect of HBs antigenemia on patient survival after renal transplantation. N Engl J Med. 1977; 296 194-196
321 Poge U, Gerhardt T, Palmedo H. et al . MDRD equations for estimation of GFR in renal transplant recipients. Am J Transplant. 2005; 5 1306-1311
322 Pol S, Wesenfelder L, Dubois F. et al . Influence of human immunodeficiency virus infection on hepatitis delta virus superinfection in chronic HBsAg carriers. J Viral Hepat. 1994; 1 131-137
323 Pollicino T, Squadrito G, Cerenzia G. et al . Hepatitis B virus maintains its pro-oncogenic properties in the case of occult HBV infection. Gastroenterology. 2004; 126 102-110
324 Pontisso P, Ruvoletto M G, Fattovich G. et al . Clinical and virological profiles in patients with multiple hepatitis virus infections. Gastroenterology. 1993; 105 1529-1533
325 Poynard T, Zoulim F, Ratziu V. et al . Longitudinal assessment of histology surrogate markers (FibroTest-ActiTest) during lamivudine therapy in patients with chronic hepatitis B infection. Am J Gastroenterol. 2005; 100 1970-1980
326 Prakoso E, Strasser S I, Koorey D J. et al . Long-term lamivudine monotherapy prevents development of hepatitis B virus infection in hepatitis B surface-antigen negative liver transplant recipients from hepatitis B core-antibody-positive donors. Clin Transplant. 2006; 20 369-373
327 Pramoolsinsap C, Poovorawan Y, Hirsch P. et al . Acute, hepatitis-A super-infection in HBV carriers, or chronic liver disease related to HBV or HCV. Ann Trop Med Parasitol. 1999; 93 745-751
328 Prieto M, Gomez M D, Berenguer M. et al . De novo hepatitis B after liver transplantation from hepatitis B core antibody-positive donors in an area with high prevalence of anti-HBc positivity in the donor population. Liver Transpl. 2001; 7 51-58
329 Propst T, Propst A, Lhotta K. et al . Reinforced intradermal hepatitis B vaccination in hemodialysis patients is superior in antibody response to intramuscular or subcutaneous vaccination. Am J Kidney Dis. 1998; 32 1041-1045
330 Protzer-Knolle U, Naumann U, Bartenschlager R. et al . Hepatitis B virus with antigenically altered hepatitis B surface antigen is selected by high-dose hepatitis B immune globulin after liver transplantation. Hepatology. 1998; 27 254-263
331 Puoti M, Airoldi M, Bruno R. et al . Hepatitis B virus co-infection in human immunodeficiency virus-infected subjects. AIDS Rev. 2002; 4 27-35
332 Puoti M, Cozzi-Lepri A, Arici C. et al . Impact of lamivudine on the risk of liver-related death in 2,041 HBsAg- and HIV-positive individuals: results from an inter-cohort analysis. Antivir Ther. 2006; 11 567-574
333 Puoti M, Torti C, Bruno R. et al . Natural history of chronic hepatitis B in co-infected patients. J Hepatol. 2006; 44 S65-S70
334 Ragni M V, Belle S H, Im K. et al . Survival of human immunodeficiency virus-infected liver transplant recipients. J Infect Dis. 2003; 188 1412-1420
335 Ragni M V, Eghtesad B, Schlesinger K W. et al . Pretransplant survival is shorter in HIV-positive than HIV-negative subjects with end-stage liver disease. Liver Transpl. 2005; 11 1425-1430
336 Rahman F, Dahmen A, Herzog-Hauff S. et al . Cellular and humoral immune responses induced by intradermal or intramuscular vaccination with the major hepatitis B surface antigen. Hepatology. 2000; 31 521-527
337 Raimondo G, Pollicino T, Cacciola I. et al . Occult hepatitis B virus infection. J Hepatol. 2007; 46 160-170
338 Ranger-Rogez S, Denis F. Hepatitis B mother-to-child transmission. Expert Rev Anti Infect Ther. 2004; 2 133-145
339 Rehermann B, Nascimbeni M. Immunology of hepatitis B virus and hepatitis C virus infection. Nat Rev Immunol. 2005; 5 215-229
340 Rendi-Wagner P, Wiedermann G, Stemberger H. et al . New vaccination strategies for low- and non-responders to hepatitis B vaccine. Wien Klin Wochenschr. 2002; 114 175-180
341 Resti M, Azzari C, Mannelli F. et al . Ten-year follow-up study of neonatal hepatitis B immunization: are booster injections indicated?. Vaccine. 1997; 15 1338-1340
342 Rizzetto M. Hepatitis D: virology, clinical and epidemiological aspects. Acta Gastroenterol Belg. 2000; 63 221-224
343 Rizzetto M. Hepatitis delta: the virus and the disease. J Hepatol. 1990; 11 (Suppl 1] S145-S148
344 Rizzetto M, Macagno S, Chiaberge E. et al . Liver transplantation in hepatitis delta virus disease. Lancet. 1987; 2 469-471
345 Rizzetto M, Verme G, Recchia S. et al . Chronic hepatitis in carriers of hepatitis B surface antigen, with intrahepatic expression of the delta antigen. An active and progressive disease unresponsive to immunosuppressive treatment. Ann Intern Med. 1983; 98 437-441
346 Robert-Koch Institut . Zur Situation wichtiger Infektionskrankheiten in Deutschland: Virushepatitis B, C und D im Jahr 2005. Epidem Bull. 2006; 46
347 Robert-Koch Institut . Mitteilungen der Ständigen Impfkommission (STIKO) am Robert-Koch-Institut: Hinweise für Ärzte zum Aufklärungsbedarf bei Schutzimpfungen. Epidem Bull. 2004; 6 33-52
348 Robert-Koch Institut . Virushepatitis B, C und D im Jahre 2004. Epidem Bull. 2005; 46 421-436
349 Robert-Koch Institut . Empfehlungen der Ständigen Impfkommission (STIKO) am Robert-Koch-Institut/Stand Juli 2006. Epidem Bull. 2006; 30 235-254
350 Roche B, Samuel D, Gigou M. et al . De novo and apparent de novo hepatitis B virus infection after liver transplantation. J Hepatol. 1997; 26 517-526
351 Rockstroh J K. Influence of viral hepatitis on HIV infection. J Hepatol. 2006; 44 S25-S27
352 Rodella A, Galli C, Terlenghi L. et al . Quantitative analysis of HBsAg, IgM anti-HBc and anti-HBc avidity in acute and chronic hepatitis B. J Clin Virol. 2006; 37 206-212
353 Romand F, Michallet M, Pichoud C. et al . Hepatitis B virus reactivation after allogeneic bone marrow transplantation in a patient previously cured of hepatitis B. Gastroenterol Clin Biol. 1999; 23 770-774
354 Roque-Afonso A M, Feray C, Samuel D. et al . Antibodies to hepatitis B surface antigen prevent viral reactivation in recipients of liver grafts from anti-HBC positive donors. Gut. 2002; 50 95-99
355 Rosenau J, Bahr M J, Tillmann H L. et al . lamivudinee and low-dose hepatitis B immune globulin for prophylaxis of hepatitis B reinfection after liver transplantation possible role of mutations in the YMDD motif prior to transplantation as a risk factor for reinfection. J Hepatol. 2001; 34 895-902
356 Rosenau J, Hooman N, Rifai K. et al . Hepatitis B virus immunization with an adjuvant containing vaccine after liver transplantation for hepatitis B-related disease: failure of humoral and cellular immune response. Transpl Int. 2006; 19 828-833
357 Rosina F, Pintus C, Meschievitz C. et al . A randomized controlled trial of a 12-month course of recombinant human interferon-alpha in chronic delta (type D) hepatitis: a multicenter Italian study. Hepatology. 1991; 13 1052-1056
358 Rosina F, Rizzetto M. Treatment of chronic type D (delta) hepatitis with alpha interferon. Semin Liver Dis. 1989; 9 264-266
359 Rosman A S, Basu P, Galvin K. et al . Efficacy of a high and accelerated dose of hepatitis B vaccine in alcoholic patients: a randomized clinical trial. Am J Med. 1997; 103 217-222
360 Rossi G, Pelizzari A, Motta M. et al . Primary prophylaxis with lamivudine of hepatitis B virus reactivation in chronic HbsAg carriers with lymphoid malignancies treated with chemotherapy. Br J Haematol. 2001; 115 58-62
361 Ruiz R, Kunitake H, Wilkinson A H. et al . Long-term analysis of combined liver and kidney transplantation at a single center. Arch Surg. 2006; 141 735-741
362 Ryu S H, Chung Y H, Choi M H. et al . Long-term additional lamivudine therapy enhances durability of lamivudine-induced HBeAg loss: a prospective study. J Hepatol. 2003; 39 614-619
363 Sadovnick A D, Scheifele D W. School-based hepatitis B vaccination programme and adolescent multiple sclerosis. Lancet. 2000; 355 549-550
364 Sagnelli E, Coppola N, Scolastico C. et al . Virologic and clinical expressions of reciprocal inhibitory effect of hepatitis B, C, and delta viruses in patients with chronic hepatitis. Hepatology. 2000; 32 1106-1110
365 Sagnelli E, Pasquale G, Coppola N. et al . Influence of chronic coinfection with hepatitis B and C virus on liver histology. Infection. 2004; 32 144-148
366 Sakallioglu O, Gok F, Kalman S. et al . Hepatitis B complicated focal segmental glomerulosclerosis. J Nephrol. 2005; 18 433-435
367 Saltik-Temizel I N, Kocak N, Demir H. Interferon-alpha and lamivudine combination therapy of children with chronic hepatitis b infection who were interferon-alpha nonresponders. Pediatr Infect Dis J. 2004; 23 466-468
368 Saltik-Temizel I N, Kocak N, Demir H. lamivudinee and high-dose interferon-alpha combination therapy for naive children with chronic hepatitis B infection. J Clin Gastroenterol. 2005; 39 68-70
369 Samuel D, Muller R, Alexander G. et al . Liver transplantation in European patients with the hepatitis B surface antigen. N Engl J Med. 1993; 329 1842-1847
370 Samuel D, Zignego A L, Reynes M. et al . Long-term clinical and virological outcome after liver transplantation for cirrhosis caused by chronic delta hepatitis. Hepatology. 1995; 21 333-339
371 Sanchez-Fueyo A, Rimola A, Grande L. et al . Hepatitis B immunoglobulin discontinuation followed by hepatitis B virus vaccination: A new strategy in the prophylaxis of hepatitis B virus recurrence after liver transplantation. Hepatology. 2000; 31 496-501
372 Saracco G, Rosina F, Brunetto M R. et al . Rapidly progressive HBsAg-positive hepatitis in Italy. The role of hepatitis delta virus infection. J Hepatol. 1987; 5 274-281
373 Sarrecchia C, Cappelli A, Aiello P. HBV reactivation with fatal fulminating hepatitis during rituximab treatment in a subject negative for HBsAg and positive for HBsAb and HBcAb. J Infect Chemother. 2005; 11 189-191
374 Schattner A. Consequence or coincidence? The occurrence, pathogenesis and significance of autoimmune manifestations after viral vaccines. Vaccine. 2005; 23 3876-3886
375 Scheiblauer H, Soboll H, Nick S. Evaluation of 17 CE-marked HBsAg assays with respect to clinical sensitivity, analytical sensitivity, and hepatitis B virus mutant detection. J Med Virol. 2006; 78 (Suppl 1] S66-S70
376 Schiff E R, Lai C L, Hadziyannis S. et al . Adefovir dipivoxil therapy for lamivudine-resistant hepatitis B in pre- and post-liver transplantation patients. Hepatology. 2003; 38 1419-1427
377 Schildgen O, Sirma H, Funk A. et al . Variant of hepatitis B virus with primary resistance to adefovir. N Engl J Med. 2006; 354 1807-1812
378 Schirmacher P, Fleig W E, Tannapfel A. et al . Bioptic diagnosis of chronic hepatitis. Results of an evidence-based consensus conference of the German Society of Pathology, of the German Society for Digestive and Metabolic Diseases and of Compensated Hepatitis (HepNet). Pathologe. 2004; 25 337-348
379 Schmilovitz-Weiss H, Ben Ari Z, Sikuler E. et al . lamivudinee treatment for acute severe hepatitis B: a pilot study. Liver Int. 2004; 24 547-551
380 Schmutz G, Nelson M, Lutz T. et al . Combination of tenofovir and lamivudine versus tenofovir after lamivudine failure for therapy of hepatitis B in HIV-coinfection. AIDS. 2006; 20 1951-1954
381 Seaworth B, Drucker J, Starling J. et al . Hepatitis B vaccines in patients with chronic renal failure before dialysis. J Infect Dis. 1988; 157 332-337
382 Segovia R, Sanchez-Fueyo A, Rimola A. et al . Evidence of serious graft damage induced by de novo hepatitis B virus infection after liver transplantation. Liver Transpl. 2001; 7 106-112
383 Seth P, Alrajhi A A, Kagevi I. et al . Hepatitis B virus reactivation with clinical flare in allogeneic stem cell transplants with chronic graft-versus-host disease. Bone Marrow Transplant. 2002; 30 189-194
384 Shattock A G, Morris M C. Evaluation of commercial enzyme immunoassays for detection of hepatitis delta antigen and anti-hepatitis delta virus (HDV) and immunoglobulin M anti-HDV antibodies. J Clin Microbiol. 1991; 29 1873-1876
385 Sheldon J, Camino N, Rodes B. et al . Selection of hepatitis B virus polymerase mutations in HIV-coinfected patients treated with tenofovir. Antivir Ther. 2005; 10 727-734
386 Sheldon J A, Corral A, Rodes B. et al . Risk of selecting K 65R in antiretroviral-naive HIV-infected individuals with chronic hepatitis B treated with adefovir. AIDS. 2005; 19 2036-2038
387 Sheng W H, Hung C C, Kao J H. et al . Impact of hepatitis D virus infection on the long-term outcomes of patients with hepatitis B virus and HIV coinfection in the era of highly active antiretroviral therapy: a matched cohort study. Clin Infect Dis. 2007; 44 988-995
388 Sherman M, Peltekian K M, Lee C. Screening for hepatocellular carcinoma in chronic carriers of hepatitis B virus: incidence and prevalence of hepatocellular carcinoma in a North American urban population. Hepatology. 1995; 22 432-438
389 Sherman M, Yurdaydin C, Sollano J. et al . Entecavir for treatment of lamivudine-refractory, HBeAg-positive chronic hepatitis B. Gastroenterology. 2006; 130 2039-2049
390 Shibolet O, Ilan Y, Gillis S. et al . lamivudinee therapy for prevention of immunosuppressive-induced hepatitis B virus reactivation in hepatitis B surface antigen carriers. Blood. 2002; 100 391-396
391 Silvestri F, Sperotto A, Ermacora A. et al . lamivudinee for the prevention of hepatitis B virus reactivation during autologous stem cell transplantation. A case report. Haematologica. 2000; 85 327-329
392 Smedile A, Farci P, Verme G. et al . Influence of delta infection on severity of hepatitis B. Lancet. 1982; 2 945-947
393 Sokal E. Drug treatment of pediatric chronic hepatitis B. Paediatr Drugs. 2002; 4 361-369
394 Sokal E M, Kelly D A, Mizerski J. et al . Long-term lamivudine therapy for children with HBeAg-positive chronic hepatitis B. Hepatology. 2006; 43 225-232
395 Soriano V, Barreiro P, Nunez M. Management of chronic hepatitis B and C in HIV-coinfected patients. J Antimicrob Chemother. 2006; 57 815-818
396 Soriano V, Puoti M, Bonacini M. et al . Care of patients with chronic hepatitis B and HIV co-infection: recommendations from an HIV-HBV International Panel. AIDS. 2005; 19 221-240
397 Spengler U, Lichterfeld M, Rockstroh J K. Antiretroviral drug toxicity - a challenge for the hepatologist?. J Hepatol. 2002; 36 283-294
398 Sponseller C A, Bacon B R, Di Bisceglie A M. Clinical improvement in patients with decompensated liver disease caused by hepatitis B after treatment with lamivudine. Liver Transpl. 2000; 6 715-720
399 Starkel P, Stoffel M, Lerut J. et al . Response to an experimental HBV vaccine permits withdrawal of HBIg prophylaxis in fulminant and selected chronic HBV-infected liver graft recipients. Liver Transpl. 2005; 11 1228-1234
400 Steinmuller T, Seehofer D, Rayes N. et al . Increasing applicability of liver transplantation for patients with hepatitis B-related liver disease. Hepatology. 2002; 35 1528-1535
401 Stevens C E, Alter H J, Taylor P E. et al . Hepatitis B vaccine in patients receiving hemodialysis. Immunogenicity and efficacy. N Engl J Med. 1984; 311 496-501
402 Su C W, Huang Y H, Huo T I. et al . Genotypes and viremia of hepatitis B and D viruses are associated with outcomes of chronic hepatitis D patients. Gastroenterology. 2006; 130 1625-1635
403 Su G G, Pan K H, Zhao N F. et al . Efficacy and safety of lamivudine treatment for chronic hepatitis B in pregnancy. World J Gastroenterol. 2004; 10 910-912
404 Sung J JY, Lai J Y, Zeuzem S. et al . A randomised double-blind phase II study of lamivudine (LAM) compared to lamivudine plus adefovir dipivoxil (ADV) for treatment naive patients with chronic hepatitis B (CHB): Week 52 analysis. Journal of Hepatology. 2003; 38 25-26
405 Tabor E. Infections by hepatitis B surface antigen gene mutants in Europe and North America. J Med Virol. 2006; 78 (Suppl 1] S43-S47
406 Tang J R, Cova L, Lamelin J P. et al . Clinical relevance of the detection of hepatitis delta virus RNA in serum by RNA hybridization and polymerase chain reaction. J Hepatol. 1994; 21 953-960
407 Tassopoulos N C, Papaevangelou G J, Sjogren M H. et al . Natural history of acute hepatitis B surface antigen-positive hepatitis in Greek adults. Gastroenterology. 1987; 92 1844-1850
408 Tenderich G, Zittermann A, Prohaska W. et al . Frequent detection of hepatitis B core antibodies in heart transplant recipients without preceding hepatitis B infection. Transplant Proc. 2005; 37 4522-4524
409 Tenney D, Baldick C J, Rose R E. et al . Only a subset of HBV substitutions at entecavir resistance residues lead to phenotypic resistance and virologic rebound. Hepatology. 2006; 44 253A-254A
410 ter Borg F, Smorenburg S, Man R A. et al . Recovery from life-threatening, corticosteroid-unresponsive, chemotherapy-related reactivation of hepatitis B associated with lamivudine therapy. Dig Dis Sci. 1998; 43 2267-2270
411 Terrault de N, Roche B, Samuel D. Management of the hepatitis B virus in the liver transplantation setting: a European and an American perspective. Liver Transpl. 2005; 11 716-732
412 Thierfelder W, Hellenbrand W, Meisel H. et al . Prevalence of markers for hepatitis A, B and C in the German population. Results of the German National Health Interview and Examination Survey 1998. Eur J Epidemiol. 2001; 17 429-435
413 Thio C L. Hepatitis B in the human immunodeficiency virus-infected patient: epidemiology, natural history, and treatment. Semin Liver Dis. 2003; 23 125-136
414 Thio C L, Seaberg E C, Skolasky Jr R. et al . HIV-1, hepatitis B virus, and risk of liver-related mortality in the Multicenter Cohort Study (MACS). Lancet. 2002; 360 1921-1926
415 Thomas H C, Lemon S, Zuckerman A J. Viral Hepatitis. Thomas HC, Lemon S, Zuckerman AJ Blackwell Publishing 2005
416 Tillmann H L, Hadem J, Leifeld L. et al . Safety and efficacy of lamivudine in patients with severe acute or fulminant hepatitis B, a multicenter experience. J Viral Hepat. 2006; 13 256-263
417 Tseng P L, Lu S N, Tung H D. et al . Determinants of early mortality and benefits of lamivudine therapy in patients with hepatitis B virus-related decompensated liver cirrhosis. J Viral Hepat. 2005; 12 386-392
418 Tsutsumi Y, Tanaka J, Kawamura T. et al . Possible efficacy of lamivudine treatment to prevent hepatitis B virus reactivation due to rituximab therapy in a patient with non-Hodgkin"s lymphoma. Ann Hematol. 2004; 83 58-60
419 Uemoto S, Inomata Y, Sannomiya A. et al . Posttransplant hepatitis B infection in liver transplantation with hepatitis B core antibody-positive donors. Transplant Proc. 1998; 30 134-135
420 Bommel van F, Wunsche T, Mauss S. et al . Comparison of adefovir and tenofovir in the treatment of lamivudine-resistant hepatitis B virus infection. Hepatology. 2004; 40 1421-1425
421 Bommel van F, Zollner B, Sarrazin C. et al . Tenofovir for patients with lamivudine-resistant hepatitis B virus (HBV) infection and high HBV DNA level during adefovir therapy. Hepatology. 2006; 44 318-325
422 Van Damme P, Kane M, Meheus A. Integration of hepatitis B vaccination into national immunisation programmes. Viral Hepatitis Prevention Board. BMJ. 1997; 314 1033-1036
423 Nunen A B, Hansen B E, Suh D J. et al . Durability of HBeAg seroconversion following antiviral therapy for chronic hepatitis B: relation to type of therapy and pretreatment serum hepatitis B virus DNA and alanine aminotransferase. Gut. 2003; 52 420-424
424 Zonneveld van M, Nunen van A B, Niesters H G. et al . lamivudinee treatment during pregnancy to prevent perinatal transmission of hepatitis B virus infection. J Viral Hepat. 2003; 10 294-297
425 Vassiliadis van T, Garipidou V, Tziomalos K. et al . Prevention of hepatitis B reactivation with lamivudine in hepatitis B virus carriers with hematologic malignancies treated with chemotherapy - a prospective case series. Am J Hematol. 2005; 80 197-203
426 Verme G, Brunetto M R, Oliveri F. et al . Role of hepatitis delta virus infection in hepatocellular carcinoma. Dig Dis Sci. 1991; 36 1134-1136
427 Villa E, Grottola A, Buttafoco P. et al . High doses of alpha-interferon are required in chronic hepatitis due to coinfection with hepatitis B virus and hepatitis C virus: long term results of a prospective randomized trial. Am J Gastroenterol. 2001; 96 2973-2977
428 Villeneuve E, Vincelette J, Villeneuve J P. Ineffectiveness of hepatitis B vaccination in cirrhotic patients waiting for liver transplantation. Can J Gastroenterol. 2000; 14 (Suppl B) 59B-62B
429 Villeneuve J P, Condreay L D, Willems B. et al . lamivudinee treatment for decompensated cirrhosis resulting from chronic hepatitis B. Hepatology. 2000; 31 207-210
430 Villeneuve J P, Durantel D, Durantel S. et al . Selection of a hepatitis B virus strain resistant to adefovir in a liver transplantation patient. J Hepatol. 2000; 39 1085-1089
431 Vo T hi DH, Bourgois A, Bontems P. et al . Chronic hepatitis B infection: long term comparison of children receiving interferon alpha and untreated controls. J Pediatr Gastroenterol Nutr. 2005; 40 141-145
432 Wai C T, Chu C J, Hussain M. et al . HBV genotype B is associated with better response to interferon therapy in HBeAg(+) chronic hepatitis than genotype C. Hepatology. 2002; 36 1425-1430
433 Wainwright R B, Bulkow L R, Parkinson A J. et al . Protection provided by hepatitis B vaccine in a Yupik Eskimo population - results of a 10-year study. J Infect Dis. 1997; 175 674-677
434 Waked I, Amin M, Abd e F. et al . Experience with interferon in chronic hepatitis B in Egypt. J Chemother. 1990; 2 310-318
435 Walker U A, Bauerle J, Laguno M. et al . Depletion of mitochondrial DNA in liver under antiretroviral therapy with didanosine, stavudine, or zalcitabine. Hepatology. 2004; 39 311-317
436 Walter J, Radun D, Claus H. et al . Hepatitis B and C risk factors in Germany - results of the national surveillance. Gesundheitswesen. 2005; 67 441-447
437 Wands J R, Chura C M, Roll F J. et al . Serial studies of hepatitis-associated antigen and antibody in patients receiving antitumor chemotherapy for myeloproliferative and lymphoproliferative disorders. Gastroenterology. 1975; 68 105-112
438 Wartelle-Bladou C, Lafon J, Trepo C. et al . Successful combination therapy of polyarteritis nodosa associated with a pre-core promoter mutant hepatitis B virus infection. J Hepatol. 2001; 34 774-779
439 Watson B, West D J, Chilkatowsky A. et al . Persistence of immunologic memory for 13 years in recipients of a recombinant hepatitis B vaccine. Vaccine. 2001; 19 3164-3168
440 Weber B. Genetic variability of the S gene of hepatitis B virus: clinical and diagnostic impact. J Clin Virol. 2005; 32 102-112
441 Wedemeyer H, Cornberg M, Tegtmeyer B. et al . Isolated anti-HBV core phenotype in anti-HCV-positive patients is associated with hepatitis C virus replication. Clin Microbiol Infect. 2004; 10 70-72
442 Weltman M D, Brotodihardjo A, Crewe E B. et al . Coinfection with hepatitis B and C or B, C and delta viruses results in severe chronic liver disease and responds poorly to interferon-alpha treatment. J Viral Hepat. 1995; 2 39-45
443 Wen Y K, Chen M L. Remission of hepatitis B virus-associated membranoproliferative glomerulonephritis in a cirrhotic patient after lamivudine therapy. Clin Nephrol. 2006; 65 211-215
444 West D J, Calandra G B. Vaccine induced immunologic memory for hepatitis B surface antigen: implications for policy on booster vaccination. Vaccine. 1996; 14 1019-1027
445 Westhoff T H, Jochimsen F, Schmittel A. et al . Fatal hepatitis B virus reactivation by an escape mutant following rituximab therapy. Blood. 2003; 102 1930
446 Westland C, Delaney W, Yang H. et al . Hepatitis B virus genotypes and virologic response in 694 patients in phase III studies of adefovir dipivoxil1. Gastroenterology. 2003; 125 107-116
447 Westland C E, Yang H, Delaney W E. et al . Week 48 resistance surveillance in two phase 3 clinical studies of adefovir dipivoxil for chronic hepatitis B. Hepatology. 2003; 38 96-103
448 Whittle H, Jaffar S, Wansbrough M. et al . Observational study of vaccine efficacy 14 years after trial of hepatitis B vaccination in Gambian children. BMJ. 2002; 325 569
449 Wiegand J, Hasenclever D, Tillman H L. Should treatment of hepatitis B depend on HBV genotypes? - A hypothesis generated from an explorative analysis of published evidence. Hepatology. 2006; 44 564A-565A
450 Williams R. Global challenges in liver disease. Hepatology. 2006; 44 521-526
451 Wintermeyer P, Gerner P, Gehring S. et al . Prevalence of hepatitis B virus precore stop codon mutations in chronically infected children. World J Gastroenterol. 2006; 12 2235-2238
452 Wismans P, Hattum van J, Stelling T. et al . Effect of supplementary vaccination in healthy non-responders to hepatitis B vaccination. Hepatogastroenterology. 1988; 35 78-79
453 Wit F W, Weverling G J, Weel J. et al . Incidence of and risk factors for severe hepatotoxicity associated with antiretroviral combination therapy. J Infect Dis. 2002; 186 23-31
454 Wolters L M, Nunen A B, Honkoop van P. et al . lamivudinee-high dose interferon combination therapy for chronic hepatitis B patients co-infected with the hepatitis D virus. J Viral Hepat. 2000; 7 428-434
455 Wong D K, Cheung A M, O"Rourke K. et al . Effect of alpha-interferon treatment in patients with hepatitis B e antigen-positive chronic hepatitis B. A meta-analysis. Ann Intern Med. 1993; 119 312-323
456 Wong D K, Yim C, Naylor C D. et al . Interferon alpha treatment of chronic hepatitis B: randomized trial in a predominantly homosexual male population. Gastroenterology. 1995; 108 165-171
457 Wong V W, Chan H L, Wong M L. et al . Clinical course after stopping lamivudine in chronic hepatitis B patients with lamivudine-resistant mutants. Aliment Pharmacol Ther. 2004; 19 323-329
458 World Health Organisation . Hepatitis Delta. Electronic Citation. 2001; , http://www.who.int/csr/
459 World Health Organisation . Hepatitis B. Electronic Citation. 2002; , http://www.who.int/csr/disease/hepatitis/HepatitisB_whocdscsrlyo2002_2.pdf
460 Wursthorn K, Buggisch P, Lutgehetmann M. et al . Temporary HBV resolution in an HIV-coinfected patient during HBV-directed combination therapy followed by relapse of HBV. Antivir Ther. 2006; 11 647-652
461 Wursthorn K, Lutgehetmann M, Dandri M. et al . Peginterferon alpha-2b plus adefovir induce strong cccDNA decline and HBsAg reduction in patients with chronic hepatitis B. Hepatology. 2006; 44 675-684
462 Yang B, Zhang B, Xu Y. et al . Prospective study of early detection for primary liver cancer. J Cancer Res Clin Oncol. 1997; 123 357-360
463 Yang H I, Lu S N, Liaw Y F. et al . Hepatitis B e antigen and the risk of hepatocellular carcinoma. N Engl J Med. 2002; 347 168-174
464 Yao F Y, Terrault N A, Freise C. et al . lamivudinee treatment is beneficial in patients with severely decompensated cirrhosis and actively replicating hepatitis B infection awaiting liver transplantation: a comparative study using a matched, untreated cohort. Hepatology. 2001; 34 411-416
465 Yeo W, Chan P K, Ho W M. et al . lamivudinee for the prevention of hepatitis B virus reactivation in hepatitis B s-antigen seropositive cancer patients undergoing cytotoxic chemotherapy. J Clin Oncol. 2004; 22 927-934
466 Yeo W, Chan P K, Zhong S. et al . Frequency of hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemotherapy: a prospective study of 626 patients with identification of risk factors. J Med Virol. 2000; 62 299-307
467 Yeo W, Johnson P J. Diagnosis, prevention and management of hepatitis B virus reactivation during anticancer therapy. Hepatology. 2006; 43 209-220
468 Yeo W, Steinberg J L, Tam J S. et al . lamivudinee in the treatment of hepatitis B virus reactivation during cytotoxic chemotherapy. J Med Virol. 1999; 59 263-269
469 Yeo W, Zee B, Zhong S. et al . Comprehensive analysis of risk factors associating with Hepatitis B virus (HBV) reactivation in cancer patients undergoing cytotoxic chemotherapy. Br J Cancer. 2004; 90 1306-1311
470 Yu A S, Vierling J M, Colquhoun S D. et al . Transmission of hepatitis B infection from hepatitis B core antibody - positive liver allografts is prevented by lamivudine therapy. Liver Transpl. 2001; 7 513-517
471 Yuen M F, Sablon E, Hui C K. et al . Factors associated with hepatitis B virus DNA breakthrough in patients receiving prolonged lamivudine therapy. Hepatology. 2001; 34 785-791
472 Yurdaydin C, Bozkaya H, Gurel S. et al . Famciclovir treatment of chronic delta hepatitis. J Hepatol. 2002; 37 266-271
473 Yurdaydin C, Wedemeyer H, Zachou K. et al . A multicenter randomised study comparing the efficacy of pegylated interferon-alpha-2a plus adefovir dipivoxil vs. pegylated interferon-alpha-2a plus placebo vs. adefovir dipivoxil for the treatment of chronic delta hepatitis. Hepatology. 2006; 44 230A
474 Zanetti A R, Mariano A, Romano L. et al . Long-term immunogenicity of hepatitis B vaccination and policy for booster: an Italian multicentre study. Lancet. 2005; 366 1379-1384
475 Zarski J P, Bohn B, Bastie A. et al . Characteristics of patients with dual infection by hepatitis B and C viruses. J Hepatol. 1998; 28 27-33
476 Zavaglia C, Severini R, Tinelli C. et al . A randomized, controlled study of thymosin-alpha1 therapy in patients with anti-HBe, HBV-DNA-positive chronic hepatitis B. Dig Dis Sci. 2000; 45 690-696
477 Zignego A L, Fontana R, Puliti S. et al . Impaired response to alpha interferon in patients with an inapparent hepatitis B and hepatitis C virus coinfection. Arch Virol. 1997; 142 535-544
478 Zollner B, Schafer P, Feucht H H. et al . Correlation of hepatitis B virus load with loss of e antigen and emerging drug-resistant variants during lamivudine therapy. J Med Virol. 2001; 65 659-663
479 Zoulim F. New insight on hepatitis B virus persistence from the study of intrahepatic viral cccDNA. J Hepatol. 2005; 42 302-308
480 Zuccotti G V, Cucchi C, Gracchi V. et al . A 1-year trial of lamivudine for chronic hepatitis B in children. J Int Med Res. 2002; 30 200-202
481 Zylberberg H, Jiang J, Pialoux G. et al . Alpha-interferon for chronic active hepatitis B in human immunodeficiency virus-infected patients. Gastroenterol Clin Biol. 1996; 20 968-971

1 Original publication: Prophylaxis, Diagnosis and Therapy of Hepatitis-B-Virus-(HBV-) Infection: upgrade of the guideline, AWMF-Register 021/011. Z Gastroenterol 2007; 45 (6): 525 - 574.

Prof. Dr. Michael P. Manns

Abteilung Gastroenterologie, Hepatologie und Endokrinologie, Medizinische Hochschule Hannover

Carl-Neuberg Str. 1

30625 Hannover

eMail: manns.michael@mh-hannover.de